A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma

Overview of attention for article published in Frontiers in oncology, February 2023

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 8 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 25,161 followers.

A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma https://t.co/3dXPfR9Lg8 https://t.co/b3Frsjmhtv

09 Feb 2023

Reply Repost Favourite

New research: A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma: Introduction High-dose interleukin-2 (HD IL-2) and pembrolizumab are each approved as single agents by the U.S. F.D.A. for the treatment of… https://t.

09 Feb 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.